Clinical trial
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a…
NCT00312039 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00312039 |
|---|---|
| Title | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation |
| Official title | A 14 Day Randomized, Double-blind, Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation |
| Acronym | Resistance |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Achillion, a wholly owned subsidiary of Alexion Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Elvucitabine, Lamivudine |
| Enrollment | 20 |
| Start date | Mar 31, 2006 |
| Primary completion | Oct 31, 2007 |
| Completion | Oct 31, 2007 |
| First posted | Apr 7, 2006 |
| Last update posted | Aug 25, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: